Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.
Cognitive impairment
Glucagon-like peptide-1 receptor agonist
NeuroD1
Tau hyperphosphorylation
Type 2 diabetes
Wnt/β-catenin pathway
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
04 09 2023
04 09 2023
Historique:
received:
15
06
2023
accepted:
21
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially, the Ex-4 ameliorates the tau hyperphosphorylation and cognitive impairment in DE. And these crucial alterations are also important bridge between T2D and AD. However, its unique mechanism is unclear. The db/db mice, high-fat-diet (HFD) / streptozotocin (STZ)-induced diabetic (HF-diabetic) mice, and high-glucose-damaged (HGD) HT-22 hippocampal cells were enrolled to examine the effects of Ex-4 on AD-like changes in T2D. The Novel object recognition test (NORT) and Morris water maze test (MWMT) were conducted to evaluate the cognitive impairment. The Dickkopf-1 (DKK1) was employed to weaken the activation of the Wnt/β-catenin pathway to explore the mechanism of Ex-4 in protecting the brain functions. The JASPAR was based to predict the interaction between NeuroD1 and the promoter region of Ins2. Moreover, the chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) and luciferase reporter assays were performed. Ex-4 alleviated the tau hyperphosphorylation, increased the brain-derived insulin, and improved the PI3K/AKT/GSK3-β signalling in db/db mice, HF-diabetic mice, and HGD HT-22 hippocampal neuronal cells. The NORT and MWMT indicated that Ex-4 alleviated the learning and memory deficits in HF-diabetic mice. The inhibitor Dickkopf-1 (DKK1) of the Wnt/β-catenin pathway significantly blocked the protective effects of Ex-4. Regarding further molecular mechanisms, NeuroD1 was affected by Ex-4 in vivo and in vitro, and the knockdown or overexpression of NeuroD1 suggested its crucial role in promoting the brain insulin by Ex-4. Meanwhile, the ChIP‒qPCR and luciferase reporter assays confirmed the combination between NeuroD1 and the promoter region of the insulin-encoding gene Ins2. And this interaction could be promoted by Ex-4. Our study proposes that Ex-4 alleviates tau hyperphosphorylation and cognitive dysfunction by increasing Ins2-derived brain insulin through the Wnt/β-catenin/NeuroD1 signaling in T2D. And its also show new lights on part of the progress and mechanism on treatment targets for the DE in T2D.
Sections du résumé
BACKGROUND
Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially, the Ex-4 ameliorates the tau hyperphosphorylation and cognitive impairment in DE. And these crucial alterations are also important bridge between T2D and AD. However, its unique mechanism is unclear.
METHODS
The db/db mice, high-fat-diet (HFD) / streptozotocin (STZ)-induced diabetic (HF-diabetic) mice, and high-glucose-damaged (HGD) HT-22 hippocampal cells were enrolled to examine the effects of Ex-4 on AD-like changes in T2D. The Novel object recognition test (NORT) and Morris water maze test (MWMT) were conducted to evaluate the cognitive impairment. The Dickkopf-1 (DKK1) was employed to weaken the activation of the Wnt/β-catenin pathway to explore the mechanism of Ex-4 in protecting the brain functions. The JASPAR was based to predict the interaction between NeuroD1 and the promoter region of Ins2. Moreover, the chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) and luciferase reporter assays were performed.
RESULTS
Ex-4 alleviated the tau hyperphosphorylation, increased the brain-derived insulin, and improved the PI3K/AKT/GSK3-β signalling in db/db mice, HF-diabetic mice, and HGD HT-22 hippocampal neuronal cells. The NORT and MWMT indicated that Ex-4 alleviated the learning and memory deficits in HF-diabetic mice. The inhibitor Dickkopf-1 (DKK1) of the Wnt/β-catenin pathway significantly blocked the protective effects of Ex-4. Regarding further molecular mechanisms, NeuroD1 was affected by Ex-4 in vivo and in vitro, and the knockdown or overexpression of NeuroD1 suggested its crucial role in promoting the brain insulin by Ex-4. Meanwhile, the ChIP‒qPCR and luciferase reporter assays confirmed the combination between NeuroD1 and the promoter region of the insulin-encoding gene Ins2. And this interaction could be promoted by Ex-4.
CONCLUSIONS
Our study proposes that Ex-4 alleviates tau hyperphosphorylation and cognitive dysfunction by increasing Ins2-derived brain insulin through the Wnt/β-catenin/NeuroD1 signaling in T2D. And its also show new lights on part of the progress and mechanism on treatment targets for the DE in T2D.
Identifiants
pubmed: 37667187
doi: 10.1186/s10020-023-00718-2
pii: 10.1186/s10020-023-00718-2
pmc: PMC10478475
doi:
Substances chimiques
Exenatide
9P1872D4OL
beta Catenin
0
Glycogen Synthase Kinase 3
EC 2.7.11.26
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Informations de copyright
© 2023. The Feinstein Institute for Medical Research.
Références
J Cell Biochem. 2013 Jul;114(7):1488-97
pubmed: 23296977
Neurobiol Dis. 2015 Dec;84:22-38
pubmed: 25926349
Diabetes Res Clin Pract. 2022 Aug;190:109970
pubmed: 35792204
Alzheimers Dement. 2014 Nov;10(6):769-78
pubmed: 25150735
J Neurochem. 2009 Oct;111(1):242-9
pubmed: 19659459
Neurosci Lett. 2017 Feb 3;639:199-206
pubmed: 28063934
J Cereb Blood Flow Metab. 2018 Mar;38(3):404-421
pubmed: 28430000
J Alzheimers Dis. 2013;33(2):329-38
pubmed: 22936005
Eur J Pharmacol. 1994 Oct 14;269(2):183-91
pubmed: 7851494
Biochem J. 2013 Feb 15;450(1):9-21
pubmed: 23343194
Cardiovasc Res. 2000 Apr;46(1):188-97
pubmed: 10727667
Psychoneuroendocrinology. 2013 Nov;38(11):2462-75
pubmed: 23790682
Front Cell Neurosci. 2014 Feb 11;8:22
pubmed: 24574966
Nat Rev Neurol. 2018 Mar;14(3):168-181
pubmed: 29377010
Diabetes. 2005 Dec;54(12):3343-8
pubmed: 16306348
J Alzheimers Dis. 2021;81(4):1403-1418
pubmed: 33935099
J Biol Chem. 2008 Mar 28;283(13):8723-35
pubmed: 18216022
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Lancet Neurol. 2022 Aug;21(8):726-734
pubmed: 35643092
Nutrients. 2020 Apr 09;12(4):
pubmed: 32283762
Arch Med Sci. 2016 Feb 1;12(1):199-207
pubmed: 26925137
J Neurochem. 2015 Oct;135(2):301-8
pubmed: 26183127
Front Neurol. 2013 Jul 01;4:83
pubmed: 23847585
Aging (Albany NY). 2020 May 11;12(9):8622-8639
pubmed: 32392535
Peptides. 1994;15(3):453-6
pubmed: 7937318
Biomed Res Int. 2014;2014:301575
pubmed: 24883305
Neurobiol Aging. 2006 Mar;27(3):451-8
pubmed: 15964100
Ter Arkh. 2016;88(10):82-86
pubmed: 28635855
Curr Alzheimer Res. 2021;18(7):546-557
pubmed: 34587885
Arch Gen Psychiatry. 1986 Nov;43(11):1067-71
pubmed: 3094475
Aging Dis. 2015 Oct 01;6(5):304-21
pubmed: 26425386
J Alzheimers Dis. 2010;19(4):1205-19
pubmed: 20308787
Lancet Neurol. 2021 Sep;20(9):739-752
pubmed: 34418401
Mol Brain. 2016 Mar 08;9:24
pubmed: 26956881
Cureus. 2021 Aug 16;13(8):e17219
pubmed: 34540446
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Eur J Pharmacol. 2004 Apr 19;490(1-3):187-97
pubmed: 15094085
Exp Neurol. 2019 Jan;311:44-56
pubmed: 30219731
Int J Obes Relat Metab Disord. 2003 Mar;27(3):313-8
pubmed: 12629557
Mol Cell Neurosci. 2016 Jan;70:68-75
pubmed: 26640240
Endocrinology. 1987 Sep;121(3):1076-82
pubmed: 3040376
Age (Dordr). 2012 Oct;34(5):1211-24
pubmed: 21901364
Gerontology. 2014;60(5):381-5
pubmed: 24732638